目的 探討芪藶強(qiáng)心膠囊聯(lián)合重組人腦利鈉肽治療擴(kuò)張型心肌病心力衰竭的臨床療效。方法 選取2014年12月-2016年11月在延安市人民醫(yī)院住院的擴(kuò)張型心肌病心力衰竭患者85例，隨機(jī)分為對(duì)照組（42例）和治療組（43例）。對(duì)照組靜脈泵入凍干重組人腦利鈉肽1.5 μg/kg，1 h后按7.5 ng/（kg·min^-1）持續(xù)泵入，72 h后給予常規(guī)治療。治療組患者在對(duì)照組治療基礎(chǔ)上口服芪藶強(qiáng)心膠囊，4粒/次，3次/d。兩組患者均連續(xù)治療2周。觀察兩組的臨床療效，比較兩組治療前后臨床指標(biāo)、心功能指標(biāo)、B型腦鈉肽（BNP）、高敏C反應(yīng)蛋白（hs-CRP）水平的變化情況。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為78.57%、90.69%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組心率、左室舒張末期內(nèi)徑（LVEDd）、收縮末期內(nèi)徑（LVESD）、BNP、hs-CRP水平均顯著降低，6 min步行距離、左心室射血分?jǐn)?shù)（LVEF）顯著升高，同組治療前后差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后，治療組心率、LVEDd、LVESD、BNP、hs-CRP水平低于對(duì)照組，6 min步行距離、LVEF高于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 芪藶強(qiáng)心膠囊聯(lián)合重組人腦利鈉肽治療擴(kuò)張型心肌病心力衰竭患者具有較好的臨床療效，可顯著改善患者的臨床癥狀和心功能指標(biāo)，降低BNP、hs-CRP水平，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To observe the clinical efficacy of Qili Qiangxin Capsules combined with recombinant human brain natriuretic peptide in treatment of dilated cardiomyopathy with heart failure. Methods Patients (85 cases) with dilated cardiomyopathy with heart failure in Yan'an People's Hospital from December 2014 to November 2016 were randomly divided into control (42 cases) and treatment (43 cases) groups. Patients in the control group were intravenous pumping with Lyophilized Recombinant Human Brain Natriuretic Peptide1.5 μg/kg, then 7.5 ng/(kg·min^-1) continuously pump after 1 h, and they were given routine treatment after 72 h. Patients in the treatment group were po administered with Qili Qiangxin Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the changes of clinical indicators, cardiac function indexes, BNP, and hs-CRP in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 78.57% and 90.69%, respectively, and there were differences between two groups (P<0.05). After treatment, heart rate, LVEDd, LVESD, BNP, and hs-CRP levels were significantly reduced, but 6 min walking distance and LVEF were significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, heart rate, LVEDd, LVESD, BNP, and hs-CRP in the treatment group were lower than those in the control group, but 6 min walking distance and LVEF were higher than those in the control group, and there was difference between two groups (P<0.05). Conclusion Qili Qiangxin Capsules combined with recombinant human brain natriuretic peptide has a significant effect in treatment of dilated cardiomyopathy with heart failure, and can significantly improve the clinical symptoms and cardiac function indexes of patients, also can reduce the levels of BNP and hs-CRP, which has a certain clinical application value.